Immunome Inc (NASDAQ: IMNM) — Perfil da empresa, notícias e dados financeiros
Immunome pioneers antibody discovery for cancer and infectious diseases, focusing on proprietary immune response research.

Immunome Inc
Immunome (NASDAQ:IMNM) is a pioneer in the field of antibody discovery and immune system targeting for the treatment of cancer and infectious diseases. Utilizing their proprietary Discovery Engine, the company aims to identify novel therapeutic antibodies through the analysis of the human immune response. Their projects are focused on developing solutions that harness the power of the immune system to fight disease more effectively. Objectives include advancing their pipeline of antibody-based therapies through clinical trials to address unmet medical needs, particularly in areas where current treatments fall short. With innovation at its core, Immunome is committed to improving patient outcomes through groundbreaking research and development.
Resumo
Operações
Produtos e/ou serviços de Immunome Inc
- Discovery Engine - A platform leveraging human memory B cells for identifying novel therapeutic antibodies.
- COVID-19 Antibody Cocktail - Designed for prevention and treatment of SARS-CoV-2 infections.
- IMM-BCP-01 - A therapeutic antibody cocktail targeting COVID-19.
- Cancer Antibody Program - Focuses on developing antibodies against targets in oncology.
- Respiratory Disease Antibody Program - Aims at creating antibodies for various respiratory diseases.
- Infectious Disease Program - Develops therapeutic and preventive antibody treatments for infectious diseases.
equipe executiva do Immunome Inc
- Clay B. SiegallChairman, President & CEO
- Max RosettChief Financial Officer
- Robert J. LechleiderChief Medical Officer
- Philip TsaiChief Technical Officer
- Jack HigginsChief Scientific Officer
- Sandra G. StonemanChief Legal Officer, General Counsel & Corporate Secretary
- Roee ShaharExecutive Vice President of Commercial
Últimas notícias sobre a Immunome Inc
Principais indicadores financeiros
Resultados divulgados pela Immunome Inc, em USD.
- Cap. de mercado
- 2,2 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 6,9 mi | -214,1 mi | -212,4 mi | |
| 9 mi | -305,8 mi | -293 mi | |
| 14 mi | -109,5 mi | -106,8 mi | |
| 6,6 mi | -36,9 mi | -36,9 mi |